Background: Systemic mastocytosis is a clonal myeloproliferative neoplasm associated with constitutional symptoms from mast cell mediated chemical and cytokine release. According to the literature, Ruxolitinib, a JAK1/JAK2 inhibitor, has been shown to reduce symptoms related to proinflammatory cytokine release in other myeloproliferative neoplasms. Case presentation: Here we present a case using Ruxolitinib for disabling constitutional symptoms despite complete bone marrow response in a patient with aggressive systemic mastocytosis. Assessment tools used to monitor symptoms in previously published Ruxolitinib trials were adopted to track symptom improvement and quality of life. Conclusions: Ruxolitinib significantly improved symptoms and quality of life in our patient with systemic mastocytosis.
CITATION STYLE
Yacoub, A., & Prochaska, L. (2016). Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis. Biomarker Research, 4(1). https://doi.org/10.1186/s40364-016-0056-5
Mendeley helps you to discover research relevant for your work.